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Abstract
Various inherited bleeding disorders deserve careful medical management 
due to their implications in women’s health. In both hemophilia A and B, almost 
exclusively, males are affected while carrier females are generally asymptomatic. 
Nevertheless, carriers may present important bleeding tendencies, which can 
eventually constitute a serious threat to life, especially after surgery or postpar-
tum. In addition, in rare but significant cases, some genetic mechanisms have 
been found to cause hemophilia in females. Aside from von Willebrand disease, 
which is the most widespread and better described hemorrhagic condition in 
women, platelet disorders and some rare clotting deficiencies cause a wide variety 
of mucocutaneous bleedings, menorrhagia, or postpartum bleeding, hence con-
stituting an important health risk. A review of the genetic and pathophysiological 
aspects as well as main clinical complications of all these conditions will allow for 
preventive practices aimed at improving the quality of life of women with bleed-
ing disorders.
Keywords: symptomatic carriers and women with hemophilia, von Willebrand 
disease, platelet disorders, rare bleeding disorders, bleedings in pregnancy and 
postpartum
1. Introduction
Inherited bleeding disorders are a group of deficiencies including the decreased 
function or number of platelets (thrombocytopenia) and clotting factor deficien-
cies, mainly von Willebrand disease (VWD), hemophilia A (HA), and hemophilia 
B (HB), as well as rare bleeding disorders (RBDs) such as deficiencies of factors (F) 
I (fibrinogen), II, FV, combined FV-FVIII, FVII, FX, FXI, and FXIII and congenital 
deficiency of vitamin K-dependent factors and plasminogen activator inhibitor 
(PAI-1). Mostly autosomal recessive, together they have a prevalence of 1:500,000 
to 1:1–3 million in the general population [1, 2].
Although all these entities cause bleeding tendencies in the affected males or 
females, there are relevant clinical issues related to obstetric and gynecological 
conditions that require special considerations in their management [1].
Menorrhagia or the more precise term of heavy menstrual bleeding (HMB) rec-
ommended by the International Federation of Gynecology and Obstetrics (FIGO) 
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is the most common symptom in women with bleeding disorders and is defined 
as bleeding that lasts more than 7 days or results in the loss of more than 80 mL of 
blood per menstrual cycle [1, 3]. In terms of women’s quality of life, HMB is defined 
as “the excessive menstrual blood loss which interferes with the woman’s physical, 
emotional, social and material quality of life, and can occur alone or in combina-
tion with other symptoms; HMB is typically associated with a symptom complex, 
including variable pelvic pain and somatic symptoms” [3].
The FIGO also classifies the dysfunctional uterine bleeding disorders and identi-
fies impaired hemostasis as one of the three recognized causes [3]. More than 70% 
of women with VWD present HMB and they are five times more likely to suffer 
from this complication than women without the condition. As for platelet disorders, 
the prevalence of HMB is 51% in women with Bernard-Soulier syndrome and 98% 
in women with Glanzmann thrombasthenia. HMB is present in 59% of women with 
FXI deficiency, in 57% of hemophilia carriers, and in 35–70% of women with other 
rare factor deficiencies [1].
In addition to HMB, women with bleeding disorders frequently suffer from large 
clots and flooding during their menstruation as well as bleeds after their men-
strual period, conditions that may seriously affect their quality of life. Since 1990, 
Higham et al. proposed a pictorial blood assessment chart (PBAC) that was based 
on a validation study against the alkaline hematin method for blood measurement, 
which is known to be very accurate and reproducible but not practical in routine 
clinical use [4]. A score greater than 100, based on the number of used tampons or 
towels and the points assigned according to the estimated blood soaking, represents 
a very good prediction and considers a menstrual blood loss of more than 80 mL 
as positive HMB. The passage of clots and flooding episodes are also registered and 
considered for the score [1, 4].
HMB can be considered a significant symptom of a bleeding disorder, especially 
when it is present at menarche. The hematological evaluation of women with HMB 
should take into account the personal and familial bleeding history of epistaxis, 
easy bruising bleeding in the oral cavity, prolonged bleeding following dental 
extraction, unexpected post-surgical bleeding, hemorrhage requiring transfusion, 
and postpartum hemorrhage, especially after 24 h [1]. In patients with at least 2–3 
symptoms, additional screening and confirmatory tests for VWD, platelet function, 
coagulation times, and clotting factor levels are mandatory [1].
Concerning the management of pregnancy and postpartum, women suspected of 
having a bleeding disorder or being a carrier of hemophilia should undergo diag-
nostic testing before getting pregnant in order to receive appropriate preconception 
counseling and early pregnancy management. This information allows for consid-
eration of the available reproductive choices and options for prenatal diagnosis such 
as planning for pregnancy and establishing the best management in terms of hemo-
static treatment and for the support of the pregnancy [1]. After the delivery, the 
elevated coagulation factor returns to the pre-pregnancy levels; therefore, the main 
risk of bleeding is after miscarriage or delivery. Postpartum hemorrhage (PPH) is a 
major cause of maternal morbidity and mortality, especially in developing countries 
or rural regions. PPH accounts for an estimated 140,000 maternal deaths each year 
worldwide and many women suffer from long-term debilitating consequences of 
the resultant anemia. Even if the most common causes of PPH are uterine atony, 
retained placenta, or genital tract trauma, coagulation disorders are also recognized 
causes of such complication [1].
In the next sections, we summarize clinical generalities, genetic aspects, impact 
on women’s health, recommended treatment, and medical management of common 
inherited bleeding disorders.
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2. Symptomatic hemophilia carriers
2.1 Generalities
Hemophilia is an X-linked disease due to mutations in the genes F8 and F9 (caus-
ing HA and HB, respectively) and subsequent deficiency of the clotting factors VIII 
(FVIII) and IX (FIX). HA affects 1/5000–10,000 males and HB 1/30,000 males. 
Both factors act in the same step of the coagulation mechanism and, when any of 
them is deficient, a diminished thrombin generation ensues. The symptoms have 
an inverse correlation with the plasmatic activity of the deficient factor, and the 
diagnosis and severity classification are based on the residual factor level [5].
2.2 Genetic aspects
Due to its recessive X-linked inheritance, males are mostly affected while the 
heterozygous female carriers are usually asymptomatic. Although some carriers 
have various bleeding manifestations and can even express severe (FVIII/FIX <0.01 
U mL-1) or moderate (FVIII/FIX 0.01–0.05 U mL-1) phenotypes, their specific clini-
cal manifestations and genetic data have hardly been described [6].
Hemophilia female carriers may be affected by hemorrhagic manifestations due 
to different genetic conditions: both mutated alleles with homozygous or compound 
heterozygous mutations in F8 or F9 genes, hemizygosity in 45,X (Turner syndrome) 
patients with a mutated X chromosome, or extremely skewed X-chromosome inacti-
vation pattern (X-IP) in carriers who have inactivated the wild-type allele and thereby 
have a highly decreased amount of the concerned factor and express the symptoms of 
the disease [7]. The molecular genetic analysis is essential in elucidating the mecha-
nisms underlying the bleeding phenotype in females with hemophilia [8–10].
In accordance with international estimations, there are 3–5 potential female car-
riers for each male with hemophilia, but not every carrier knows her genetic status. 
According to the study of Bernard, only 38% of the potential carriers have been 
screened about their carrier/non-carrier status. He analyzed 408 potential carri-
ers and reported that only a limited fraction of them received information from a 
hemophilia specialist about their status and underwent coagulation factor analysis; 
the remaining large fraction failed to accomplish the screening due to lack of com-
munication within the family and unawareness of the inheritance mode [11].
If women do not realize the possibility of being carriers, all their symptoms 
can be overlapped with normal women and those with VWD or qualitative platelet 
disorders [7]; so, all possible or potential carriers must be screened and should be 
advised about care and surveillance regarding bleeding tendencies [12].
2.3 Clinical features
Different studies have shown the increased tendency of bleeding in hemophilia 
carriers compared to healthy females. Olsson et al. described the bleeding symp-
toms in 126 hemophilia carriers in contrast to 90 non-hemophilia carriers; the 
hemorrhagic tendency was normal in 82 carriers (65%) and in all but two women 
in the control group (98%). They reported that there was no difference in bleeding 
symptoms between carriers from hemophiliac families and carriers with sporadic 
mutations. The proportion of carriers and controls reporting bleeding symptoms 
was different with statistically significant results (p < 0.001), Table 1 [13].
Paroskie compared 44 HA carriers with 43 healthy women and found a signifi-
cant (p < 0.05) increase in clinical features as shown in Table 2 [5]. Contrary to 
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what would be expected, laboratory results do not always correlate with the clinical 
picture. A comparison of FVIII:C/FIX:C levels, hemoglobin, platelets, and fibrino-
gen between symptomatic hemophilia carriers and asymptomatic carriers did not 
reveal significant differences, yet a subgroup of carriers with factor levels within the 
lower normal range exhibited increased blood symptoms [14].
Srivaths et al. compared the bleeding complications in adolescents and adults 
and found that anemia and gynecologic procedures/surgeries were less frequent 
in adolescents likely because of an early detection [15]. On the other hand, in the 
case of HB due to Hemophilia B Leyden mutation (c.-22T>C) in the promotor of 
F9 gene, there is a physiological mechanism that tends to normalize the FIX plasma 
levels according to age, which is mainly mediated by growth hormones rather than 
androgens that may ameliorate the bleeding symptoms in patients and female 
 carriers [16].
2.4 Impact on women’s health
The time between the start of bleeding symptoms and the diagnosis of a 
FVIII/FIX deficiency is often prolonged. Di Michele et al. reported that the mean 
period of diagnosis for hemophilia carriers with severe FVIII/FIX deficiency was 
8.5 months compared to 2 months for similarly affected males; but if the deficiency 
was moderate, the diagnosis was delayed for 48 months compared to 4 months for 
similarly affected men [6].
The most common symptom, HMB, can have a significant impact on quality of 
life, missed days at work/school, iron deficiency anemia, need for hospitalization or 
blood transfusions, and higher costs in medical care [7]. Delayed diagnosis situ-
ates affected women at risk for co-morbidity and even mortality depending on the 
Clinical features Carriers (%) Controls (%)
Heavy menstrual bleeding 70 5
Cutaneous bruising 65 40
Oral cavity bleeding 50 25
Post-surgical bleeding 48 9
Hematomas 35 8
Postpartum bleeding 30 8
Hemarthrosis 18 0
Taken from the study of Paroskie [5].
Table 2. 
Clinical traits related to hemorrhages in hemophilia carriers and normal women.
Clinical features Carriers (%) Controls (%)
Menorrhagia 37 16
Bleeding from minor wounds 32 0
Surgery 32 7.2
Tooth extraction 30 0
Nosebleed 24 4.4
Cutaneous bleeding 17 1.1
Taken from information reported by Olsson et al. [13].
Table 1. 
Bleeding symptoms in hemophilia carriers and normal women.
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clinical context; this is why the carrier status and the percentage of clotting factor 
should be determined, and a proper genetic counseling should be offered [15].
2.5 Treatment
Dose, intervals, and duration for treatment depend on the clinical situation, 
effectiveness, and laboratory test results [7]. The treatment may include tranexamic 
acid, oral contraceptive pills (in some HMB), or factor VIII/IX [7, 15]. Hemostatic 
plans for hemophilia carriers with severe or mild FVIII/FIX deficiency should be 
noticed among primary care physicians and specialists in gynecology/obstetrics, 
hematology, orthopedics, clinical genetics, etc. Although each patient requires a 
personalized management, here we describe general guidelines for the treatment of 
the main hemorrhagic disorders in women:
2.5.1 HMB
Adolescents and women with HMB often respond well to standard therapies 
such as combined oral contraception pills, progestin-only pills, intrauterine devices, 
or antifibrinolytics such as aminocaproic acid or tranexamic acid. These therapies 
are warranted as the two key mechanisms in HMB are excessive local fibrinolytic 
mechanisms and inhibition of platelet function [7].
2.5.2 During pregnancy
The management of a hemophilia carrier should be coordinated among the 
hematologist, obstetrician, and anesthetist. During pregnancy, plasma levels of von 
Willebrand factor (VWF) and FVIII may rise sufficiently to permit safe hemo-
stasis without exogenous hemostatic support, but they should be re-examined at 
32–34 weeks of pregnancy; if the levels are less than 50% and more particularly less 
than 30% of the reference ranges, DDAVP or FVIII concentrates may be used. In 
pregnancy, FIX levels do not rise [17]. The use of DDAVP in symptomatic carriers 
of FVIII deficiency is controversial because the prescriber’s information advises 
that the drug is contraindicated with lactation and recommends precaution during 
pregnancy. This drug has been used in the first and second trimester in 27 symp-
tomatic carriers without adverse events [18]. Moreover, symptomatic carriers with 
factor levels less than 50% should receive a recombinant factor to prevent bleeding 
at delivery or spinal anesthesia [19]. Determination of fetal sex and prenatal hemo-
philia testing in any at-risk pregnancy are essential for planning the safe delivery of 
an affected female.
DDAVP is also indicated for HA patients with factor VIII coagulant activity 
levels greater than 5%. Intravenous dose is 0.3 μg/kg IV over 15–30 minutes (for 
pre-op, 30 minutes before the procedure). Intranasal administration is indicated for 
patients with FVIII levels >5% at a dose of 50 μg (if the patient’s weight is <50 kg) or 
300 μg (if weight ≥ 50 kg) 2 h before any surgical procedure [20].
2.6 Recommended integral management
Management of females represents a special challenge due to the risk of menor-
rhagia or postpartum bleeding, the large proportion (almost 40%) of unaware 
hemophilia carriers, and the medical inexperience of hemophilia in women.
The successful management in symptomatic hemophilia carriers requires the 
coordination of hematology, obstetrics/gynecology, orthopedics, and the coagula-
tion laboratory as well as a complete education of the hemophilia carriers with 
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the aim of providing them the best available information on the risk of bleeding, 
genetic implications in the offspring, reproductive options, and antenatal manage-
ment of the affected offspring and mother [19].
3. von Willebrand disease in women
3.1 Generalities
VWD is the most common inherited bleeding disorder with a worldwide preva-
lence of 1% [21], associated with mucocutaneous and postoperative bleeding that is 
caused by a qualitative or quantitative defect of the VWF [22], a glycoprotein that 
participates in primary and secondary hemostasis via platelet adhesion at the site 
of the endothelial injury and platelet aggregation with the formation of the platelet 
plug, not to mention its role in transporting and stabilizing the FVIII [23].
VWD does not present sex, ethnic, or geographic predilection; however, the 
number of symptomatic women is greater than that of men in most populations 
(ratio 2:1) due to menstrual and delivery bleeding disorders [24]. The International 
Society on Thrombosis and Hemostasis (ISTH) recognizes six types of VWD [25] 
depending on the amount and functional activity of VWF. There can be a partial 
or total quantitative defect (type 1 and 3) or a qualitative defect (type 2) [26]. 
Moreover, type 2 VWD is subdivided into 4 variants (2A, 2B, 2M, and 2N) based on 
the details of the patient’s phenotype [27].
3.2 Genetic aspects
The VWF gene, also known as VWD, is located at 12p13.3 and has a length 
of 178 kilobases (kb), and its 52 exons are transcribed into a 9 kb mRNA that 
encodes a pre-pro-VWF protein of 2813 amino acids whose different domains 
interact with other proteins and perform specific functions [28]. The expres-
sion of the VWF gene is limited to endothelial cells and megakaryocytes [29]. 
Different mutations cause quantitative (VWD types 1 and 3) or qualitative 
(type 2) defects in the VWF protein. VWD mostly has an autosomal dominant 
inheritance; only types 3 and 2N (in some cases type 2A) are inherited in an 
autosomal recessive manner [22].
3.3 Clinical features
Clinical manifestations of VWD could arise only when a hemostatic challenge 
occurs and include the following main symptoms:
• Excessive mucocutaneous bleeding.
• Hematoma with minimal trauma.
• Recurrent and prolonged epistaxis.
• Gingival hemorrhage.
• Prolonged bleeding after some dental procedure, surgery, or trauma.
• HMB (the most common symptom in women) or prolonged or excessive bleed-
ing after delivery.
7Clinical Issues in Women with Inherited Bleeding Disorders
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• Gastrointestinal bleeding, particularly in patients with type 2A VWD.
• Patients with type 3 and type 2N VWD may have hemarthroses due to a low level 
of FVIII [30].
3.4 Impact on women’s health
HMB occurs in approximately 80% of cases and is associated with significant 
co-morbidity, namely iron deficiency anemia, stress, and reduction in the quality of 
life affecting daily activities; in addition, it entails higher costs in medical care [31]. 
There is evidence that women with VWD have higher rates of postpartum hemor-
rhage and transfusions at the time of delivery compared to healthy women [32].
Under normal conditions, postpartum hemorrhage is controlled due to the 
progressive increased activity of VWF and FVIII during pregnancy that reaches its 
maximum level at the time of delivery and subsequently decreases to a baseline level 
in approximately 1 month [32]. In VWD patients, the amount, functional activity, 
and behavior of VWF vary according to the disease’s type and FVIII concentration 
Figure 1 [33]. Although the function of the placenta may be impaired, there are 
inconsistent results about the risk of abortion in women with VWD [34].
Under normal conditions, a doubling of the levels of FVIII and VWF (VWF: Ag) 
and functional activity of the VWF (VWF: RCo) can be observed. Patients with 
severe VWD type 1 (increased clearance) do not show a significant increase in 
levels of VWF and FVIII. On the other hand, in type 1 there is a progressive increase 
in VWF levels; however, it is not as high as in normal conditions. In type 2A, the 
functional activity of VWF remains low due to the absence of high molecular 
weight multimers, and in type 2M the ratio of VWF: Ag/VWF: RCo is affected due 
to the low increase in VWF: RCo. In type 2N, FVIII remains reduced due to the 
inability of the VWF to bind to FVIII. Taken from Castaman [33].
3.5 Treatment
Because VWD is the most common cause of HMB, appropriate tests (measure-
ment of VWF: Ag and VWF: RCo) should be performed to establish an accurate 
diagnosis and the specific treatment for the disease [35].
Figure 1. 
Behavioral patterns of VWF and FVIII under normal conditions and in different VWD subtypes during 
pregnancy.
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The treatment focuses on two central aspects: increasing the concentration of 
functional VWF available for hemostasis and providing complementary therapies 
to stabilize it [36]. DDAVP is administered intravenously or intranasally to increase 
plasmatic VWF through the release of endogenous VWF stored in Weibel-Palade 
bodies of endothelial cells. DDAVP is used in hemostatic challenges such as dental 
extractions and moderate nosebleeds or menorrhagia [36]. The administration of 
recombinant VWF is recommended in patients who do not respond to DDAVP or 
that require sustained levels of VWF in severe hemostatic challenges such as trauma 
and surgery [36]. Additional therapies include antifibrinolytic agents, amino-
caproic acid, and tranexamic acid, which are recommended in mild to moderate 
bleedings. They are often used as adjunctive therapy in addition to concentrates of 
DDAVP or VWF in surgery or delivery [36].
3.6 Recommended integral management
Management in women presents a special challenge due to HMB and possible 
complications during pregnancy [37]. The successful management of pregnancy 
involves the coordination of obstetrics, anesthesia, and the coagulation laboratory 
that monitors levels of VWF: RCo and FVIII:C [37].
4. Platelet disorders
4.1 Idiopathic thrombocytopenic purpura (ITP)
4.1.1 Generalities
Idiopathic thrombocytopenic purpura or immune thrombocytopenia (ITP) 
is the most common acquired blood disorder. In this disease, autoantibodies 
against platelets render them susceptible to rapid clearance from the circulation 
[38–40]. Although the mechanism of origin of these antibodies is unknown, 
they belong to the gamma-globulin fraction expressed on platelet membranes 
and destroy the platelets [41–43] via their interaction with certain surface 
glycoproteins (GPs) identified as GP IIb-IIIa, GP Ib, and GP V [43]. The GP 
IIb-IIIa complex is the antigenic target in most patients. Platelets with antibod-
ies are removed by splenic macrophages; however, their reactivation can lead to 
ineffective thrombopoiesis [40].
4.1.2 Genetic aspects
A positive family history is suggestive of hereditary thrombocytopenia. In addition 
to a presumptive autosomal dominant ITP, it has been found that the receptor for the 
Fc region of complexed immunoglobulin gamma (FCGR2C) predisposes to the disease 
[44, 45]. Several of their polymorphisms are related to the development of immuno-
logical reactions, but their contribution as a cause of ITP is still uncertain [46].
4.1.3 Clinical features
ITP can be acute or chronic and is characterized by (1) thrombocytopenia 
<150 × 109 L−1 without other identifiable cause, (2) purpuric rash, and (3) normal 
function of bone marrow. Its approximate incidence is 3 to 8 per 100,000 children 
per year [43]. Acute ITP is frequent in children aged <10 years who have low platelet 
counts (usually 20,000 to 30 × 109 L−1). The onset of signs and symptoms is often 
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preceded by a viral illness. Chronic ITP affects mainly adolescents with platelet 
counts of 20-70×109 L-1. Females are affected more frequently than males and are 
more likely to exhibit an underlying autoimmune disorder. Yet, the disease may be 
asymptomatic [43].
According to duration, ITP can be (1) newly diagnosed (<3 months), (2) persistent 
(between 3 and 6 months), or (3) chronic (>12 months). The clinical presentation can 
be (1) severe, patients with relevant bleeding, or requiring additional interventions or 
increased drug dose, or (2) refractory, severe clinical manifestations after splenectomy. 
Platelet counts define two types: (1) ≥100×109 L-1 measured on 2 occasions with more 
than 7 days between each sampling and (2) ≥30×109 L-1 and a greater than twofold 
increase in platelet count measured on 2 occasions >7 days apart [47].
Typical clinical presentation affects apparently healthy individuals; begins with 
easy bruising and purpuric rash [40]; and evolves to nasal, gingival, gastrointestinal 
tract, vaginal, urinary tract, retina, or conjunctivae bleedings. Bone marrow smears 
show normal or increased megakaryocytes, whereas plasma thrombopoietin levels 
are decreased. Patients with 10-20×109 L-1 of platelet counts are at increased risk for 
intracranial hemorrhage (ICH) [43].
4.1.4 Impact on women’s health
About 7% of pregnancies or 1-10 in 10,000 pregnant women are diagnosed 
with gestational ITP (<150×109 L-1 of platelet count) generally in the first trimester 
[48, 49]. Only near 30% requires treatment and support from a multidisciplinary 
team [39, 50]. Recommended first-line therapy is intravenous immunoglobulin or 
corticosteroids, which have similar efficacy for platelet count increase. The latter 
may have mild toxicity for the mother and fetus, but usual adverse effects include 
weight gain, hyperglycemia, and hypertension [39].
4.1.5 Treatment
The pharmacologic management of acute ITP continues being controversial, 
because in approximately 80% of patients the disease is self-limited and disap-
pears in the first 6 months after diagnosis without medication. For the 20% of 
patients who progress to the chronic type [43], prednisone at a standard dose of 
1 mg/kg/day for 2–4 weeks is the first choice drug [39]. Yet, a randomized clinical 
trial has shown that it is better to use high-dose pulsed dexamethasone (40 mg/
day for 4 days) than standard prednisone therapy in adult patients with immune 
thrombocytopenia [51].
4.1.6 Recommended integral management
Integral management of a patient with ITP is based on support measures (reduce 
physical activity, wear protective head-gear, adapt protective padding to the crib, 
avoid medications that affect platelets, and keep a constant evaluation and dental 
care) sometimes complemented with pharmacological and surgical treatment [43]. 
Patients require consulting a hematologist.
4.2 Bernard-Soulier syndrome
4.2.1 Generalities
Bernard-Soulier syndrome (BSS) results from a deficiency of platelet gly-
coprotein protein Ib (GPIb), which mediates the initial interaction of platelets 
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with the subendothelial components via the von Willebrand protein. It is a rare 
but severe bleeding disorder in which platelets do not aggregate in response to 
ristocetin. Platelets from BSS patients lack a major surface membrane glycopro-
tein complex called GPIb-IX-V that functions as a receptor for VWF and whose 
absence causes giant platelets [52]. This complex is the initial contact for adhesion 
of platelets in damaged vessels, mediates the interaction with VWF (GPIb-IX-V/
VWF), and interacts with the platelet cytoskeleton [52, 53]. The GPIb-IX-V 
complex comprises GPIbα, GPIbβ, GPIX, and GPV proteins whose assemblage 
forms the receptor [54].
4.2.2 Genetic aspects
BSS usually results from autosomal recessive mutations in GP1BA, GP1BB, and 
GP9 genes that code for 3/4 proteins of the GPIb-IX-V complex (mutations in the 
4th gene involved, GP5, are unreported) [52, 54]. Compound heterozygous patients 
outnumber homozygous patients. Only a few cases result from autosomal dominant 
mutations [55]. Although BSS carriers are usually asymptomatic with normal platelet 
counts, sometimes they show slightly enlarged platelets, slightly decreased GPIb-IX-V 
complex expression, and/or a moderately reduced ristocetin response [55, 56].
4.2.3 Clinical and hematological features
Clinical presentation of BSS is characterized by epistaxis, gingival and cutane-
ous bleeding, hemorrhages post trauma, prolonged skin bleeding time, thrombo-
cytopenia, and large platelets. Patients often suffer from mucocutaneous bleedings 
of different severity [54]. In females, it can be associated with severe menorrhagia 
[52]. Typically, platelet counts are low, and the platelets are so large (often the size 
of red blood cells) that they may be missed on blood counts because most automatic 
counters do not count them as platelets [40]. The clinical laboratory assessment of 
GPIb-IX-V/VWF interaction with platelets reveals impaired platelet agglutination 
after stimulation with ristocetin [52, 54, 57].
4.2.4 Impact on women’s health
Some women with BSS require oral contraceptive treatment for menorrhagia 
and even platelet transfusions in cases of severe bleeding [57]. Generally, pregnan-
cies of patients with BSS are not complicated [58]. However, if during the delivery 
the patient presents severe bleeding, platelet transfusions or hysterectomy can be 
performed to control it [59].
4.2.5 Treatment
Usually, platelet transfusions are effective as BSS treatment; the inconvenience 
is the alloantibody development against GpIb [56]. Transfusions must be used 
only for severe bleeding and emergencies [40]. Also, the use of DDAVP, epsilon-
aminocaproic acid (EACA), and recombinant factor VIIa (rVIIa) has been approved 
as an effective therapy for some patients [56].
4.2.6 Recommended integral management
BSS care is generally based on support measures only, inclusive for dental care. 
Actually, most patients do not require medication. The use of antiplatelet treatment 
must be avoided, and a hematologist should be consulted for its prescription [60].
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4.3 Glanzmann thrombasthenia
4.3.1 Generalities
Glanzmann thrombasthenia (GT) is a rare dysfunction of the platelet integrin 
receptor CD41 (GPIIb/IIIa complex) that prevents the formation of aggregates in 
response to many agents, except for ristocetin [40, 56]. There are two GT types 
according to the functionality of the GP IIb/IIIa complex; type I is caused by the total 
absence of the GP IIb/IIIa complex and exhibits a more severe phenotype; type II is 
usually milder because some of the GP IIb/IIIa complexes are functional [40].
4.3.2 Genetic aspects
GT is an autosomal recessive disorder due to diverse mutations of the multi-subunit 
GpIIb/IIIa complex [56, 61–63]. The carriers or heterozygotes are asymptomatic, 
although they show a 50% reduction in the number of GpIIb/IIIa molecules [56]. 
ITGA2B and ITGB3 genes code for proteins GPIIb and GPIIIa, respectively, and both 
are located at 17q21 [64]. GT is frequent in regions where consanguineous marriages 
are common [65, 66].
4.3.3 Clinical features
Clinical manifestations are variable in severity and frequency and depend on the 
genotype. Bleeding symptoms are present in patients homozygous or compound 
heterozygous for GPIIb/IIIa mutations [67]. As a minimum symptom, the patients 
have lifelong mucosal bleeding [56]. The bleeding (epistaxis, gingival hemorrhage, 
and menorrhagia) can be frequent, severe, and sometimes fatal [62, 68]. Severe 
epistaxis is common, mainly in childhood. Some patients only had bruising. Less 
commonly, gastrointestinal bleeding and hematuria have been observed [69]. The 
platelet count, morphology, and size are normal [56].
4.3.4 Impact on women’s health
The transfusion history of red cell and/or platelet is frequent. Affected women 
are at risk of severe HMB and bleeding during pregnancy and delivery [69].
4.3.5 Treatment
The standard treatment for continuous bleeding has been platelet transfusions, 
especially for patients refractory to local measures and/or antifibrinolytic drugs 
[70]. However, the efficacy of platelet transfusion is limited by alloantibodies 
against platelets [56]. Several authors of clinical trials recommend the use of rFVIIa 
in the management of intractable epistaxis. It has been documented that this agent 
is effective in the management of bleeding or during surgeries at doses from 120 to 
300 μg/kg [71, 72].
4.3.6 Recommended integral management
GT is a hemorrhagic lifelong disorder that requires integral support measures. 
Most patients have a history of transfusions indicated for severe bleeding [40, 67].  
Fortunately, the prognosis of patients is good due to supportive care, and the 
disease has limited effect on their daily lives [69]. Dental and hematological advice 
is recommended.
Hemophilia - Recent Advances
12
5. Rare bleeding disorders (RBDs) in pregnancy and postpartum
5.1 Generalities
RBDs account for 3–5% of all inherited coagulation conditions and are charac-
terized by a wide variability of bleeding symptoms that range from mild to severe 
in individuals affected by the same disorder. Most commonly, mucocutaneous 
bleeding and post-surgery hemorrhage are observed. Affected women usually 
suffer from menorrhagia, spontaneous abortion, and bleeding after delivery 
[73]. Although most RBDs are autosomal recessive traits, some cases of FXI 
deficiency and hypo- and dysfibrinogenemia are autosomal dominant. According 
to the epidemiological data of the World Federation of Hemophilia (WFH) and 
European Network of the Rare Bleeding Disorders (EN-RBDs), the prevalence of 
each deficiency among the total affected population is as follows: FVII (39%), FXI 
(26%), Fibrinogen, FV and FX (8–9%), FXIII (6%), combined FV + FVIII (3%), 
and FII (1%) [73].
Medical management and treatment of the RBSs are suboptimal because of their 
very low frequency. As a result, affected individuals received delayed diagnosis, 
incomplete laboratory testing, and limited treatment options. Standardization of coag-
ulation assays, global clotting assays, and genomic sequencing promises to improve the 
diagnosis of RBDs, but there is still a long gap to overcome [1]. Table 3 shows a general 
scope of the physiological characteristics, symptoms, and impact of the RBDs.
Deficiency Plasma 
level  
(μg/mL)
Bleeding 
symptoms
Laboratory 
diagnosis
Prevalence Gene 
(chromosome)
Fibrinogen 1500–4000 Umbilical cord, 
hemarthrosis, 
mucosal tract, 
menorrhagia,  
first trimester 
abortion, 
CNS Venous, 
and arterial 
thromboembolism 
are reported
Afibrinogenemia:
APTT↑↑, PT↑↑, 
TT↑↑,  
dys-
hypofibrinogenemia: 
APTT↑, PT↑↑, TT↑↑
1:1,000,000 FGA, FGB,  
and FGG 
(4q28)
F II 100 Umbilical cord, 
hemarthrosis, and 
mucosal tract
APTT↑↑, PT↑  
TT normal
1:2,000,000 F2 (11p11-q12)
F V 10 Mucosal tract and 
postoperative
APTT↑, PT↑,  
TT normal
1: 1,000,000 F5 (1q24.2)
F VII 0.13–1.0 Mucosal tract, 
hemarthrosis, 
hematomas, and 
neonatal CNS 
hemorrage
APTT normal, 
PT↑, TT normal
1: 500,000 F7 (13q34)
F X 10 Umbilical cord, 
hemarthrosis, 
hematomas, and 
CNS hemorrhages
APTT↑, PT↑,  
TT normal
1: 1,000,000 F10 (13q34)
F XI 3–6 Oral cavity, post-
traumatic, and 
postoperative
APTT↑, ↑T, PT 
normal, TT normal
1: 1,000,000 F11 (4q35.2)
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5.2 RBDs in pregnancy, delivery, and puerperium
Women with RBDs require especial medical treatment and care. In addi-
tion to common bleeding symptoms, they may also experience gynecological 
bleeding and are at increased risk of hemorrhagic ovarian cysts, endometriosis, 
and endometrial hyperplasia polyps and fibroids. Pregnancy and childbirth in 
women with RBDs are real clinical challenges; miscarriages, bleeding during 
pregnancy, and postpartum hemorrhage are frequent and may represent severe 
clinical complications [74].
There has been a higher risk of diverse obstetric complications reported in 
women with RBDs; miscarriage and placental abruption resulting in fetal loss or 
preterm delivery are rather common in women deficient in fibrinogen or factor XIII 
(FXIII) [1].
To resolve the clinical complications of women with RBDs, it is important 
to consider the behavior of the clotting factors in normal conditions and their 
tendency to increase during pregnancy that has been attributed to the increase 
of estrogen concentrations, especially in the third trimester (fibrinogen, FVII, 
FVIII, FX, FXII, FXIII, and VWF). Other factors (FII, V, IX, and XIII) increase 
slightly or remain unchanged while FXI is the only factor that decreases during 
pregnancy [75].
6. Conclusion
Inherited bleeding disorders may seriously impact the women’s quality of life 
through their detrimental effects on academic, professional, and social life. Long-
lasting HMB causes iron deficiency anemia with consequences on physical and 
mental well-being. Medical care for women with bleeding disorders is lacking in 
many countries and there may be cultural taboos and obstacles preventing women 
Deficiency Plasma 
level  
(μg/mL)
Bleeding 
symptoms
Laboratory 
diagnosis
Prevalence Gene 
(chromosome)
F XIII 10–20 Umbilical cord, 
spontaneous CNS 
hemorrhages, 
miscarriages, and 
abnormal scarring
APTT normal, PT 
normal, TT normal 
specific FXIII assay
1: 2,000,000 F13A1 
(6p24-p25)
F13B 
(1q31-q32.1)
FV + FVIII As for 
each 
factor
Mucosal tract and 
postoperative
APTT↑, PT↑,  
TT normal
1: 1,000,000 LMAN1 
(18q21.3-q22)
MCFD2 
(2p21-p16.3)
VKCFD As for 
each 
factor
Umbilical cord, 
CNS hemorrhages, 
and postoperative 
(children may 
show skeletal 
abnormalities)
APTT↑, PT↑↑,  
TT normal
<50 families GGCX (2p12)
VKORC1 
(16p11.2)
CNS, central nervous system; APTT, activated partial thromboplastin time; PT, prothrombin time. Taken from 
Castaman and Linari [73].
Table 3. 
Clinical symptoms and laboratory/molecular diagnosis in rare bleeding disorders (RBDs).
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from seeking help, specifically for menstrual problems, which may lead to marital 
disharmony and possibly fertility problems. Caregivers are often unaware about 
bleeding disorders in women, and therefore, even when women do seek help, the 
diagnosis is often neglected and appropriated treatment is not provided. In addi-
tion, bleeding disorders in women have negative consequences on the nutrition and 
well-being of their children. Early identification of young girls and women with 
HMB for managing their menstruation and iron deficiency is crucial in improving 
women’s health in general [1].
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Appendices and nomenclature
BSS Bernard-Soulier syndrome
DDAVP 1-deamino-8-D-arginine vasopressin, denominated as 
desmopressin
EACA epsilon-aminocaproic acid
FCGRC2 receptor for the Fc region of complexed immunoglobulin gamma
FIGO The International Federation of Gynecology and Obstetrics
FIX:C factor IX procoagulant activity
FVIII:C factor VIII procoagulant activity
FXIII factor XIII protein
F8 factor 8 gene
F9 factor 9 gene
GPIb platelet glycoprotein protein Ib
GPs platelet surface glycoproteins
GT Glanzmann thrombasthenia
HA hemophilia A
HB hemophilia B
HMB heavy menstrual bleeding
ICH Intracranial hemorrhage
ISTH International Society on Thrombosis and Hemostasis
ITP idiopathic thrombocytopenic purpura or immune 
thrombocytopenia
IVIg Intravenous immunoglobulin
Kb Kilobases
PAI-1 plasminogen activator inhibitor
PBAC pictorial blood assessment chart
PPH postpartum hemorrhage
RBDs rare bleeding disorders
rVIIa recombinant factor VIIa
15
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Clinical Issues in Women with Inherited Bleeding Disorders
DOI: http://dx.doi.org/10.5772/intechopen.82119
Author details
Ana-Rebeca Jaloma-Cruz1*, Isaura-Araceli González-Ramos2,  
Diana Ornelas-Ricardo3, Clara-Ibet Juárez-Vázquez2 and Hilda Luna-Záizar4
1 Genetics Division, Biomedical Research Center of Occident, Mexican Institute of 
Social Security, Guadalajara, Jalisco, Mexico
2 Genetics Department, Institute of Biological Sciences, Medicine Faculty, 
Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
3 PhD Program on Human Genetics, University Center of Health Sciences, 
University of Guadalajara, Guadalajara, Jalisco, Mexico
4 Department of Chemistry, University Center of Exact Sciences and Engineering, 
University of Guadalajara, Guadalajara, Jalisco, Mexico
*Address all correspondence to: arjaloma@gmail.com
VWD von Willebrand disease
VWF von Willebrand factor
VWF:Ag antigen test of the VWF used to measure the amount of VWF
VWF:RCo a ristocetin cofactor test used to measure functional activity of the 
VWF
16
Hemophilia - Recent Advances
[1] Kadir RA, James AH. Reproductive 
Health in Women with Bleeding 
Disorders. World Federation of 
Hemophilia, Treatment of Hemophilia 
Series; 2009. Vol. 48. pp. 1-13. Available 
from: http://www.wfh.org
[2] Hermans C, Kulkarni R. Women 
with bleeding disorders. Hemophilia. 
2018;24:29-36. DOI: 10.1111/hae.13502
[3] Fraser IS, Critchley HOD, Broder M.  
The FIGO recommendations on 
terminologies and definitions for 
normal and abnormal uterine 
bleeding. Seminars in Reproductive 
Medicine. 2011;29:383-390. DOI: 
10.1055/s-0031-1287662
[4] Higham JM, O’Brien PM, Shaw RW.  
Assessment of menstrual blood loss 
using a pictorial chart. British Journal 
of Obstetrics and Gynaecology. 
1990;97:734-739. DOI: 10.1111/j.1471-
0528.1990.tb16249.x
[5] Paroskie A, Gailani D, DeBraun MR. 
A cross-sectional study of bleeding 
phenotype in haemophilia A carriers. 
British Journal of Haematology. 
2015;170:223-228. DOI: 10.1111/
bjh.13423
[6] Di Michele DM, Gibb C, Lefkowitz 
JM. Severe and moderate haemophilia 
A and B in US females. Haemophilia. 
2014;20:e136-e143. DOI: 10.1111/
hae.12364
[7] Staber J, Croteau SE, Davis J. The 
spectrum of bleeding in women and 
girls with haemophilia B. Haemophilia. 
2018;24:180-185. DOI: 10.1111/
hae.13376
[8] Pavlova A, Brondke H, Müsebeck 
J. Molecular mechanisms underlying 
hemophilia A phenotype in seven 
females. Journal of Thrombosis and 
Haemostasis. 2009;7:976-982. DOI: 
10.1111/j.1538-7836.2009.03346.x
[9] Khan MTS, Naz A, Ahmed J. 
Diagnosis and phenotypic assessment 
of Pakistani haemophilia B carriers. 
Pakistan Journal of Medical Sciences. 
2017;33:738-742. DOI: 10.12669/
pjms.333.12496
[10] Olsson A, Ljung R, Hellgren M. 
Phenotype and genotype comparisons in 
carriers of haemophilia A. Haemophilia. 
2016;22:e235-e237. DOI: 10.1111/
hae.12928
[11] Bernard W, Lambert C, Henrard S.  
Screening of haemophilia carriers in 
moderate and severe haemophilia A 
and B: Prevalence and determinants. 
Haemophilia. 2018;24:e142-e144. DOI: 
10.1111/hae.13468
[12] Lavaut K. Importancia del 
diagnóstico de portadoras en familias 
con antecedentes de hemofilia. Revista 
Cubana de Hematologia e Inmunología 
y Hemoterapia. 2014;30:108-113. ISBN 
0864-0289
[13] Olsson A, Hellgren M, 
Berntorp E. Association between 
bleeding tendency and health-
related quality of life in carriers of 
moderate and severe haemophilia. 
Haemophilia. 2015;21:742-746. DOI: 
10.1111/hae.12796
[14] Olsson A, Hellgren M, Berntorp E.  
Clotting factor level is not a good 
predictor of bleeding in carriers 
of haemophilia A and B. Blood 
Coagulation & Fibrinolysis. 
2014;25:471-475. DOI: 10.1097/
MBC.0000000000000083
[15] Srivaths LV, Zhang QC, Byams VR. 
Differences in bleeding phenotype and 
provider interventions in postmenarchal 
adolescents when compared to adult 
women with bleeding disorders and 
heavy menstrual bleeding.  
Haemophilia. 2018;24:63-69. DOI: 
10.1111/hae.13330
References
17
Clinical Issues in Women with Inherited Bleeding Disorders
DOI: http://dx.doi.org/10.5772/intechopen.82119
[16] Hildyard C, Keeling D. Effect of 
age on factor IX levels in symptomatic 
carriers of haemophila B Leyden. British 
Journal of Haematology. 2015;169: 
448-449. DOI: 10.1111/bjh.13223
[17] Street AM, Ljung R, Lavery SA.  
Management of carriers and 
babies with haemophilia. 
Haemophilia. 2008;14:181-187. DOI: 
10.1111/j.1365-2516.2008.01721.x
[18] Mannucci PM. Use of desmopressin 
(DDAVP) during early pregnancy 
in factor VIII-deficient women. 
Blood. 2005;105:3382. DOI: 10.1182/
blood-2004-11-4472
[19] Lavee O, Kidson-Gerber G. 
Update on inherited disorders of 
haemostasis and pregnancy. Obstetric 
Medicine. 2016;9:64-72. DOI: 
10.1177/1753495X15624307
[20] Medscape Drug Reference [Internet]; 
Lundberg. 2018. Available from: https://
reference.medscape.com/drug/ddavp-
stimate-noctiva-desmopressin-342819 
[Accessed: July 7, 2018]
[21] Pikta M, Zemtsovskaja G, Bautista 
H. Preclinical evaluation of a semi-
automated and rapid commercial 
electrophoresis assay for von Willebrand 
factor multimers. Journal of Clinical 
Laboratory Analysis. 2018;32:e22416. 
DOI: 10.1002/jcla.22416
[22] De Jong A, Eikenboom J. 
Developments in the diagnostic 
procedures for von Willebrand disease. 
Journal of Thrombosis and Haemostasis. 
2016;14:449-460. DOI: 10.1111/
jth.13243
[23] Stockschlaeder M, Schneppenheim 
R, Budde U. Update on von Willebrand 
factor multimers: Focus on high-
molecular-weight multimers and their 
role in hemostasis. Blood Coagulation 
& Fibrinolysis. 2014;25:206-216. DOI: 
10.1097/MBC.00000000000 
00065
[24] Lillicrap D. von Willebrand 
disease: Advances in pathogenetic 
understanding diagnosis and therapy. 
Blood. 2013;122:3735-3740. DOI: 
10.1182/asheducation-2013.1.254
[25] Favaloro EJ, Bonar RA, Meiring M.  
Evaluating errors in the laboratory 
identification of von Willebrand disease 
in the real world. Thrombosis Research. 
2014;134:393-403. DOI: 10.1016/j.
thromres.2014.05.020
[26] Lehner S, Ekhlasi-Hundrieser M, 
Detering C. A 12.3-kb duplication 
within the VWF gene in pigs affected 
by von Willebrand disease type 3. 
G3 (Bethesda). 2018;8:577-585. DOI: 
10.1534/g3.117.300432
[27] Nichols WL, Hultin MB, 
James AH. von Willebrand disease 
(VWD): Evidence based diagnosis 
management guidelines, the National 
Heart, Lung and Blood Institute 
(NHLBI), expert Panel report (USA). 
Haemophilia. 2008;14:171-232. DOI: 
10.1111/j.1365-2516.2007.01643.x
[28] VWF von Willebrand factor [Homo 
sapiens (human)]—Gene—NCBI 
[Internet]. 2018. Available from: https://
www.ncbi.nlm.nih.gov/gene/7450 
[Accessed: July 10, 2018]
[29] Xiang Y, Hwa J. Regulation of 
VWF expression, and secretion in 
health and disease. Current Opinion 
in Hematology. 2016;23:288-293. DOI: 
10.1097/MOH.0000000000000230
[30] Sharma R, Flood VH. Advances 
in the diagnosis and treatment of von 
Willebrand disease. Hematology. 
American Society of Hematology. 
Education Program. 2017;1:379-384. 
DOI: 10.1182/asheducation-2017.1.379
[31] Ragni MV, Machin N, Malec LM. 
von Willebrand factor for menorrhagia: 
A survey and literature review. 
Haemophilia. 2016;22:397-402. DOI: 
10.1111/hae.12898
Hemophilia - Recent Advances
18
[32] James AH, Konkle BA, Kouides P.  
Postpartum von Willebrand factor 
levels in women with and without von 
Willebrand disease and implications for 
prophylaxis. Haemophilia. 2015;21: 
81-87. DOI: 10.1111/hae.12568
[33] Castaman G. Changes of von 
Willebrand Factor during Pregnancy 
in Women with and without von 
Willebrand Disease. Mediterranean 
Journal of Hematology and Infectious 
Diseases.  2013;5:2013052. DOI: 
10.4084/MJHID.2013.052
[34] Skeith L, Rydz N, O’Beirne M. 
Pregnancy loss in women with von 
Willebrand disease: A single-center 
pilot study. Blood Coagulation & 
Fibrinolysis. 2017;28:393-397. DOI: 
10.1097/MBC.0000000000000620
[35] Lee C, Kadir A, Kouides P. Women 
with von Willebrand disease. In: Federici 
A, Lee C, editors. von Willebrand 
Disease: Basic and Clinical Aspects. 1st 
ed. Chichester: Wiley; 2011. pp. 174-185
[36] Ng CJ, Paola D, von Willebrand 
Disease J. Diagnostic strategies and 
treatment options. Pediatric Clinics of 
North America. 2018;65:527-541. DOI: 
10.1016/j.pcl.2018.02.004
[37] Neff AT, Sidonio RF Jr. Management 
of VWD. Hematology. American Society 
of Hematology. Education Program. 
2014;2014:536-541. DOI: 10.1182/
asheducation 2014.1.536
[38] Ahn YS, Horstman LL. Idiopathic 
thrombocytopenic purpura: 
Pathophysiology and management. 
International Journal of Hematology. 
2002;76:123-131. PMID: 12430912
[39] Lambert MP, Gernsheimer TB.  
Clinical updates in adult immune 
thrombocytopenia. Blood. 
2017;129:2829-2835. DOI: 10.1182/
blood-2017-03-754119
[40] Medscape Drug Reference. 
Platelet Disorders Overview of Platelet 
Disorders [Internet]. 2017. Available 
from: https://emedicine.medscape.
com/article/201722-overview#showall 
[Accessed: July 24, 2018]
[41] Harrington WJ, Minnich V, 
Hollingsworth JW. Demonstration of a 
thrombocytopenic factor in the blood 
of patients with thrombocytopenic 
purpura. Journal of Laboratory and 
Clinical Medicine. 1951;115:636-645. 
PMID: 2187937
[42] Arimura G, Harrington WJ, Minnich 
V. The autoimmune thrombocytopenias. 
Progress in Hematology. 1956;1:166-192. 
PMID:13359508
[43] Chu YW, Korb J, Sakamoto KM. 
Idiopathic thrombocytopenic purpura. 
Pediatrics in Review. 2000;21:95-104. 
PMID: 10702324
[44] Breunis WB, van Mirre E, Bruin M. 
Copy number variation of the activating 
FCGR2C gene predisposes to idiopathic 
thrombocytopenic purpura. Blood. 
2008;111:1029-1038. DOI: 10.1182/
blood-2007-03-079913
[45] Online Mendelian Inheritance in 
Man (OMIM). Thrombocytopenic 
purpura autoimmune (OMIM 188030) 
[Internet]. 2009. Available from: 
https://www.omim.org/entry/188030#9 
[Accessed: July 24, 2018]
[46] U.S. National Library of Medicine. 
Genetics Home Reference. Immune 
thrombocytopenia [Internet]. 
2018. Available from: https://ghr.
nlm.nih.gov/condition/immune-
thrombocytopenia#genes [Accessed: 
July 25, 2018]
[47] Rodeghiero F, Stasi R, Gernsheimer T. 
Standardization of terminology, 
definitions and outcome criteria in 
immune thrombocytopenic purpura 
of adults and children: Report from an 
international working group. Blood. 
2009;113:2386-2393. DOI: 10.1182/
blood-2008-07-162503
19
Clinical Issues in Women with Inherited Bleeding Disorders
DOI: http://dx.doi.org/10.5772/intechopen.82119
[48] Kelton JG. Idiopathic 
thrombocytopenic purpura 
complicating pregnancy. Blood 
Reviews. 2002;16:43-46. DOI: 10.1054/
blre.2001.0181
[49] American College of Obstetricians 
and Gynecologists. ACOG practice 
bulletin: Thrombocytopenia in 
pregnancy. Number 6, September 
1999. Clinical management guidelines 
for obstetrician-gynecologists. 
International Journal of Gynecology 
& Obstetrics. 1999;67:117-128. PMID: 
10636060
[50] Webert KE, Mittal R, Sigouin C.  
A retrospective 11-year analysis of 
obstetric patients with idiopathic 
thrombocytopenic purpura. Blood. 
2003;102:4306-4311. DOI: 10.1182/
blood-2002-10-3317
[51] Matschke J, Müller-Beissenhirtz 
H, Novotny J. A randomized trial 
of daily prednisone versus pulsed 
dexamethasone in treatment-
naïve adult patients with immune 
thrombocytopenia: EIS 2002 Study. 
Acta Haematologica. 2016;136:101-107. 
DOI: 10.1159/000445420
[52] Lopez JA, Andrews RK, Afshar-
Kharghan V. Bernard-Soulier syndrome. 
Blood. 1998;91:4397-4418. PMID: 
9616133
[53] Andrews R, Berndt M, Lopez J. The 
glycoprotein Ib-IX-V complex. In: 
Michelson AD, editor. Platelets. 2nd ed. 
San Diego, CA: Academic Press; 2006. 
pp. 145-164
[54] Li R, Emsley J. The organizing 
principle of the platelet glycoprotein 
Ib-IX-V complex. Journal of Thrombosis 
and Haemostasis. 2013;11:605-614. DOI: 
10.1111/jth.12144
[55] Noris P, Perrotta S, Bottega R. 
Clinical and laboratory features of 103 
patients from 42 Italian families with 
inherited thrombocytopenia derived 
from the monoallelic Ala156Val mutation 
of GPIb alpha (Bolzano mutation). 
Haematologica. 2012;97:82-88. DOI: 
10.3324/haematol.2011.050682
[56] Handin RI. Inherited platelet 
disorders. Hematology American 
Society of Hematology Education 
Program. 2005;1:396-402. DOI: 10.1182/
asheducation-2005.1.396
[57] Savoia A, Pastore A, De Rocco D. 
Clinical and genetic aspects Bernard-
Soulier syndrome: Searching for 
genotype/phenotype correlations. 
Haematologica. 2011;96:417-423. DOI: 
10.3324/haematol.2010.032631
[58] Peng TC, Kickler TS, Bell WR. 
Obstetric complications in a patient 
with Bernard-Soulier syndrome. 
American Journal of Obstetrics and 
Gynecology. 1991;165:425-426. PMID: 
1714677
[59] Peaceman AM, Katz AR, Laville M. 
Bernard-Soulier syndrome complicating 
pregnancy: A case report. Obstetrics 
and Gynecology. 1989;73:457-459. 
PMID: 2915873
[60] Medscape Drug Reference. Bernard-
Soulier Syndrome Treatment & 
Management [Internet]. 2016. Available 
from: https://emedicine.medscape.com/
article/954877-treatment [Accessed: 
July 24, 2018]
[61] D’Andrea G, Colaizzo D, Vecchione 
G. Glanzmann’s thrombasthenia: 
Identification of 19 new mutations 
in 30 patients. Thrombosis and 
Haemostasis. 2002;87:1034-1042. 
PMID: 12083483
[62] Bellucci S, Caen J. Molecular basis 
of Glanzmann’s thrombasthenia and 
current strategies in treatment. Blood 
Reviews. 2002;16:193-202. PMID: 
12163005
[63] Nair S, Ghosh K, Kulkarni B. 
Glanzmann’s thrombasthenia: Updated. 
Hemophilia - Recent Advances
20
Platelets. 2002;13:387-393. DOI: 
10.1080/0953710021000024394
[64] Rosenberg N, Yatuv R, Sobolev V. 
Major mutations in calf-1 and calf-2 
domains of glycoprotein IIb in patients 
with Glanzmann thrombasthenia 
enable GPIIb/IIIa complex formation, 
but impair its transport from the 
endoplasmic reticulum to the Golgi 
apparatus. Blood. 2003;101:4808-4815. 
DOI: 10.1182/blood-2002-08-2452
[65] Newman PJ, Seligsohn U, Lyman S.  
The molecular genetic basis of 
Glanzmann thrombasthenia in the Iraqi-
Jewish and Arab populations in Israel. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 1991;88:3160-3164. PMID: 
2014236
[66] Toogeh G, Sharifian R, Lak M. 
Presentation and pattern of symptoms 
in 382 patients with Glanzmann 
thrombasthenia in Iran. American 
Journal of Hematology. 2004;77: 
198-199. DOI: 10.1002/ajh.20159
[67] Franchini M, Favaloro EJ, Lippi G. 
Glanzmann thrombasthenia: An update. 
Clinica Chimica Acta. 2010;411:1-6. 
DOI: 10.1016/j.cca.2009.10.016
[68] Nurden AT, George JN. Inherited 
abnormalities of the platelet membrane: 
Glanzmann thrombasthenia, Bernard-
Soulier syndrome, and other disorders. 
In: Hemostasis and Thrombosis, Basic 
Principles and Clinical Practice. 6th ed. 
Philadelphia: Lippincott, Williams & 
Wilkins; 2005. pp. 987-1010
[69] Nurden AT. Glanzmann 
thrombasthenia. Orphanet Journal 
of Rare Diseases. 2006;6, 1:10. DOI: 
10.1186/1750-1172-1-10
[70] Poon MC, Zotz R, Di Minno G. 
Glanzmann’s thrombasthenia treatment: 
A prospective observational registry on 
the use of recombinant human activated 
factor VII and other hemostatic 
agents. Seminars in Hematology. 
2006;43:S33-S536. DOI: 10.1053/j.
seminhematol.2005.11.009
[71] Valentino LA. Use of rFVIIa 
in 4 children with Glanzmann 
thromboasthenia. Journal of 
Pediatric Hematology/Oncology. 
2006;28:653-658. DOI: 10.1097/01.
mph.0000212993.49188.73
[72] Franchini M. The use of 
recombinant activated factor VII 
in platelet disorders: A critical 
review of the literature. Blood 
Transfusion. 2009;7:24-28. DOI: 
10.2450/2008.0015-08
[73] Castaman G, Linari S. Diagnosis and 
treatment of von Willebrand disease 
and rare bleeding disorders. Journal of 
Clinical Medicine. 2017;6:1-18. DOI: 
10.3390/jcm6040045
[74] Palla R, Peyvandy F, Shapiro AD. 
Rare bleeding disorders: Diagnosis 
and treatment. Review Series. Blood. 
2015;125:2052-2061. DOI: 10.1182/
blood-2014-08-532820
[75] Hellgren M. Hemostasis during 
normal pregnancy and puerperium. 
Seminars in Thrombosis and 
Hemostasis. 2003;29:125-130. DOI: 
10.1159/000217305
